FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

TorreyPines to liquidate after fire sale fizzles

Tools

With no white knight appearing from stage left with a buyout offer, the board at TorreyPines Therapeutics has decided to call it quits and join the ranks of the liquidated.

The decision to shutter the company comes three years after TorreyPines went public with about $80 million in the bank. That money is largely gone now, along with most of the company's staff. Only three staffers were left on duty after TorreyPines decided in March to stop all efforts aside from finding a buyer or some other eleventh-hour solution to its woes.

TorreyPines has been slipping steadily since the fall of 2007, when investors turned their thumbs down on new data for the developer's migraine therapy. The company listed $6.7 million in assets and $4.9 million in liabilities in its most recent quarterly report. TorreyPines battered stock closed at 31 cents on Friday.

- read the report from the San Diego Union-Tribune

Related Articles:
TorreyPines goes virtual, looks at strategic alternatives
TorreyPines sells Alzheimer's rights to Eisai
Troubled TorreyPines plans new round of layoffs
TorreyPines plans layoffs in streamlining


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about TorreyPines Therapeutics   bankruptcy   Biotech graveyard